Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide vs Observation in Asymptomatic High-Risk Smoldering Multiple Myeloma
NCT01169337Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2011
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of lenalidomide in smoldering multiple myeloma (SMM), sponsored by National Cancer Institute. Started Jan 2011; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT01169337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01169337.